Cytotoxic Chemotherapy for Pancreatic Cancer
Authors:
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (8) , 1059-1072
Abstract
Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. However, the efficacy of chemotherapy is limited. Gemcitabine is the only agent that improves symptoms and confers a modest survival advantage. Many combination therapy regimens have been studied in phase II settings. Eleven randomised phase III trials have been conducted to compare gemcitabine-containing regimens with gemcitabine monotherapy since gemcitabine became available clinically. The combination of gemcitabine plus capecitabine has demonstrated a survival advantage over gemcitabine, whereas gemcitabine plus oxaliplatin and gemcitabine plus cisplatin have shown improved progression-free survival or time to tumour progression but failed to demonstrate a survival advantage over gemcitabine. The search for effective therapy for advanced pancreatic cancer continues. Gemcitabine in combination with cytotoxic agents or molecular targeted agents hold promise.Keywords
This publication has 73 references indexed in Scilit:
- Gemcitabine Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for the Treatment of Advanced Carcinoma of the PancreasChemotherapy, 2004
- Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic CancerOncology, 2004
- Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II studyAnnals of Oncology, 2003
- Phase II Study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Patients With Pancreatic CancerSeminars in Oncology, 2001
- A phase II studyEuropean Journal of Cancer, 2000
- A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)Oncology, 2000
- A phase II trial of topotecan in patients with previously untreated pancreatic cancerAnti-Cancer Drugs, 1996
- Activity of cisplatin in adenocarcinoma of the pancreasEuropean Journal of Cancer, 1993
- A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreasEuropean Journal of Cancer, 1992
- Phase II study of epirubicin in advanced adenocarcinoma of the pancreasEuropean Journal of Cancer and Clinical Oncology, 1985